A time-honored tradition in business media is searching through companies’ annual reports to see just how much they pay their treasured CEOs. As of this year, thanks to a provision in the Dodd-Frank law, it’s also possible to learn the median pay among employees at these companies.

In biopharma, that pay is pretty ample.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Is the ratio of CEO to median pay a real indication of effective CEO pay or more of a issue with the median pay to all employees (i.e. Geron lowest CEO to Employee ratio 5.4 X versus Geron with the highest median pay/employee of $500K. What would the chart look like if a broader assumption was made and a targeted median pay was used at X ( propose – $100k) level for large Pharma vs Y (propose $200K) for small/mid cap company (assuming median pay is higher to balancersik of working with a smaller company)

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy